Compare Medpace Holdings Inc (MEDP) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Redwire Corporation — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while Redwire Corporation trades at $9.18 (market cap $2.05B). The key difference: Medpace Holdings Inc is far larger — about 7.4× Redwire Corporation's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| MEDP | RDW | |
|---|---|---|
Market Cap | $15.08B | $2.05B |
Sector | Technology | Technology |
52-Week High | $620.59 | $25.90 |
52-Week Low | $308.88 | $5.06 |
Enterprise Value | $14.55B | $2.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
RDW trades at $8.60, down 1.78% on the day, with a bearish technical signal despite bullish oscillators. The company reported a net loss of $226.55 million in 2025, with negative margins and cash flow from operations. Recent news highlights a record $498 million backlog and contract wins, but concerns over dilution and losses persist. The stock is near its support levels with resistance at $9.
The outlook is mixed: strong analyst buy ratings and a $19 consensus price target suggest upside, but fundamental weaknesses and cash burn pose significant risks. Investment opportunity hinges on execution improving profitability, while key risks include continued losses and competitive pressures in the aerospace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
